預測測試市場規模、佔有率、按測試類型、技術、應用、最終用戶和地區分類的成長分析 - 2025 年至 2032 年產業預測

2023 年全球預測測試市場規模為 49 億美元，預計將從 2024 年的 53.6 億美元成長到 2032 年的 109.1 億美元，預測期內（2025-2032 年）的複合年成長率為 9.3%。

醫療技術領域正在經歷顯著成長，這得益於人們對早期疾病檢測的日益關注和預測工具的進步。人們對早期檢測益處的認知不斷提高，以及更準確、更實惠的檢測方法的開發，使得這些解決方案對患者和醫療保健提供者都具有吸引力。政府和私人組織透過資金和政策舉措提供的支持將進一步加強創新和採用的環境。然而，障礙包括高成本，特別是在中低收入國家，以及對資料隱私和道德的擔憂。基因組學和生物資訊學的持續創新以及對精準醫療的關注開闢了巨大的成長機會。相關人員之間的合作對於克服障礙和確保市場的長期永續性至關重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 生態系測繪
• 市場吸引力指數（2023年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 技術分析
• 監管格局

預測測試市場規模（按測試類型和複合年成長率） (2025-2032)

• 市場概覽
• 基因檢測
• 生物標記檢測
• 家族病史評估
• 多基因風險評分

預測測試市場規模（依技術及複合年成長率） (2025-2032)

• 市場概覽
• 次世代定序
• 微陣列分析
• 桑格定序
• PCR檢測

預測測試市場規模（按應用分類）及複合年成長率（2025-2032）

• 市場概覽
• 腫瘤學
• 心臟病學
• 神經病學
• 罕見遺傳疾病

預測測試市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 診斷實驗室
• 研究機構
• 家庭檢測套組

預測測試市場規模（按地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Veracyte, Inc.
• Abbott
• 23andMe, Inc.
• PharmaMar
• Quest Diagnostics Incorporated
• Celerion
• Myriad Genetics, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Genomic Health
• Caris Life Sciences
• Natera, Inc.
• F. Hoffmann-La Roche
• Exact Sciences Corporation
• BioAxis DNA Research Centre Private Limited
• Color Genomics, Inc.
• Direct Laboratory Services LLC（DirectLabs）
• Gene Ltd.
• Pathway Genomics Corporation
• Positive Bioscience, Inc.

結論和建議

Global Predictive Presymptomatic Testing market was valued at USD 4.9 Billion in 2023 and is expected to grow from USD 5.36 Billion in 2024 to USD 10.91 Billion by 2032, with a CAGR of 9.3% during the forecast period (2025-2032).

The healthcare technology sector is experiencing significant growth, fueled by rising interest in early disease detection and advancements in predictive tools. Increased awareness of the benefits of early detection, coupled with the development of more accurate and affordable testing methods, makes these solutions appealing to both patients and healthcare providers. Support from government and private organizations through funding and policy initiatives further enhances the environment for innovation and adoption. However, barriers such as high costs, especially in low- and middle-income countries, and concerns over data privacy and ethics pose challenges. Continuous innovation in genomics and bioinformatics, along with a focus on precision medicine, opens up substantial growth opportunities. Collaborative efforts among stakeholders will be crucial for overcoming hurdles and ensuring the long-term sustainability of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Predictive Presymptomatic Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Predictive Presymptomatic Testing Market Segments Analysis

The global predictive presymptomatic testing market is segmented into test type, technology, application, end user, and region. By test type, the market is classified into genetic testing, biomarker testing, family history assessment, and polygenic risk score. Depending on technology, it is divided into next-generation sequencing, microarray analysis, sanger sequencing, and PCR-based testing. According to application, the market is categorized into oncology, cardiology, neurology, and rare genetic disorders. Based on End User, the market is segmented into hospitals, diagnostic laboratories, research institutions, and home testing kits. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Driver of the Global Predictive Presymptomatic Testing Market

The increasing prevalence of chronic noncommunicable diseases (NCDs) like cancer, diabetes, and cardiovascular ailments is fueling the demand for presymptomatic predictive testing. According to the World Health Organization (WHO), NCDs account for a staggering 74% of global deaths, with a significant 86% of these preventable fatalities occurring in low- and middle-income countries. Forecasts from countries such as England and India indicate a dramatic rise in disease incidence, highlighting the critical importance of early detection in improving health outcomes and alleviating the pressures on healthcare systems. This growing urgency underscores the necessity for advanced predictive testing solutions on a global scale.

Restraints in the Global Predictive Presymptomatic Testing Market

Despite significant advancements that have driven genome sequencing costs below USD 100, the high overall expenses associated with performing next-generation sequencing (NGS) assays, ranging from USD 5,000 to USD 7,000, remain a formidable barrier. This challenge is exacerbated by limited reimbursement policies, particularly in low- and middle-income countries. The World Health Organization emphasizes the importance of equitable access to healthcare as a means to reduce disparities globally. Consequently, these financial limitations impede the widespread adoption of presymptomatic testing technologies, highlighting the urgent need for improved funding and policy support to facilitate access and drive market growth.

Market Trends of the Global Predictive Presymptomatic Testing Market

The Global Predictive Presymptomatic Testing market is experiencing a significant surge, driven by the convergence of genomics and digital health technologies. In the short term, governments and healthcare organizations prioritize the integration of genetic testing with digital platforms, enhancing patient care through precision medicine initiatives like the European Union's Horizon Europe. This investment fosters the development of digital solutions that facilitate seamless data sharing and remote monitoring, ultimately enabling personalized health coaching and disease prevention. As a result, predictive presymptomatic testing becomes increasingly convenient and accessible, catering to a growing demand for proactive health management and tailored healthcare solutions globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2023
• Pestel Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study
• Technology Analysis
• Regulatory Landscape

Global Predictive Presymptomatic Testing Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Genetic Testing
• Biomarker Testing
• Family History Assessment
• Polygenic Risk Score

Global Predictive Presymptomatic Testing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Next-Generation Sequencing
• Microarray Analysis
• Sanger Sequencing
• PCR-Based Testing

Global Predictive Presymptomatic Testing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Cardiology
• Neurology
• Rare Genetic Disorders

Global Predictive Presymptomatic Testing Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutions
• Home Testing Kits

Global Predictive Presymptomatic Testing Market Size & CAGR (2025-2032)

• North America (Test Type, Technology, Application, End User)
  • US
  • Canada
• Europe (Test Type, Technology, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Technology, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Technology, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Technology, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Veracyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 23andMe, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharmaMar
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celerion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioAxis DNA Research Centre Private Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Color Genomics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Direct Laboratory Services LLC (DirectLabs)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pathway Genomics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Positive Bioscience, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations